SynerFuse® is a Minnesota-based medical device company innovating the spine industry with its integrated approach to spinal fusion and chronic pain. The patented SynerFuse® procedure, Electric Transforaminal Lumbar Interbody Fusion™ (e-TLIF™), combines fusion with direct nerve stimulation to address chronic low back and leg pain that is unaddressed in traditional spinal fusion surgery that provide Ultra Low Energy™ (ULE™) Therapy.

Our History

While there were numerous spinal fusion product companies and several that operated in the neurostimulation market, none had the vision to combine the two therapy modalities of spinal fusion and neuromodulation into a single solution implanted simultaneously at the point of a spinal fusion procedure.

SynerFuse® was founded in 2018 with this vision. Subsequently, the company identified an enormous whitespace opportunity and built a deep and broad intellectual property portfolio around it, creating the SynerFuse® e-TLIF™ (Electronic Transforaminal Lumber Interbody Fusion™) procedure enables ULE™ (Ultra Low Energy™) Therapy solution that integrates spinal fusion and neuromodulation.

In 2022, the first SynerFuse® e-TLIF™ patented procedure was performed at the University of Minnesota, M Health Fairview. In 2023, enrollment in the company’s proof-of-concept study-involving 15 e-TLIF™ procedures--was completed. In 2024, final patient exited proof-of-concept study. In 2025, proof-of-concept study was completed. From the data and learnings from the e-TLIF™ procedure SynerFuse is designing and building its NeuroFuse® System which is an ULE™ Therapy to prepare for Pivotal Trial.

The Spinal Fusion Market and Pain Management Opportunity

There are more than 570,000 spinal fusion procedures performed annually in the United States alone, and the market is expected to grow steadily based on our aging population and the high obesity rates. As many as 40% of cases result in chronic, residual pain following a spinal fusion surgery, costing the US healthcare system $20B annually. A common treatment pathway is a narcotic-based regimen. If that is not successful, neurostimulation is sought in a two-step process: a trial and a final implant, thus subjecting a patient to three surgical procedures. In contrast, the SynerFuse® approach involves the combined implantation of a spinal fusion device and our SynerFuse® device concept.

SynerFuse® Milestones

SynerFuse® completed its proof-of-concept study to evaluate the safety and tolerability of the Electric Transforaminal Lumbar Interbody Fusion (e-TLIF™) procedure, an Ultra Low Energy™ (ULE™) Therapy, integrating spinal fusion with direct nerve stimulation, which is designed to treat neuropathic chronic low back pain (cLBP). Based on the data and learnings from the e-TLIF™ procedure, the company will finalize its design and build its NeuroFuse® System which is an ULE™ Therapy to prepare for Pivotal Trial. Concurrent with this activity, SynerFuse® will continue to build out its intellectual property portfolio, and implement regulatory and reimbursement strategies.